Loading...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus
Na minha lista:
| Udgivet i: | Ann Transl Med |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
AME Publishing Company
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6015935/ https://ncbi.nlm.nih.gov/pubmed/29955590 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2018.02.20 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|